UNSPSC 51142557: Memantine hydrochloride

This classification denotes an antiparkinsonian agent with the molecular formula C12H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JY0WD0UA60, chemically known as 3,5-dimethyltricyclo(3.3.1.1(3,7))decan-1-amine but more generally known as memantine hydrochloride, which bears US NIH Compound Identifier 4054. European Medicines Agency schedules Memantine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03137MIG.

Most nations, for tariff and trade purposes, schedule memantine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, MEMANTINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Memantine hydrochloride bears US NLM identifiers UMLS ID C0771988 and NCI Concept Code C47601. SMILES: C[C@@]12CC3C[C@@](C1)(C[C@](C3)(C2)N)C.CL.

UNSPSC 51142557 Memantine hydrochloride is a Commodity code that does not reflect the actual scope of recent state and local procurement activity posted under it. The three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical supply agreements—none of which center on memantine or its clinical applications. State and local health agencies, cooperative purchasing alliances, and county health departments are the issuing bodies, but the mismatch between the code's nominal substance and the work being solicited suggests the code is either misapplied in the source data or serves as a placeholder for a broader pharmaceutical-category taxonomy that state and local procurement systems have not yet refined.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission issued an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities on direct-to-manufacturer pharmacy programs outside traditional pharmacy benefit manager structures; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with awarded vendors effective July 1, 2026. The code shows little relevant recent activity tied to memantine itself and does not provide a clear signal for business development targeting state or local procurement under its stated name.